Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: A double-blind randomised parallel group placebo-controlled trial

Human Psychopharmacology

Volumn 18, Issue 4, 2003, Pages 271-275

  Wynchank, Dora ^a   Berk, Michael ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Akathisia; Extrapyramidal side effects; Nefazodone; Parkinsonism

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; PARALLEL DESIGN; PATIENT SELECTION; POSTSYNAPTIC INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR BLOCKING; TARDIVE DYSKINESIA;

ACUTE DISEASE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; RECEPTORS, SEROTONIN, 5-HT2; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SUBSTANCE-RELATED DISORDERS; TRIAZOLES;

EID: 0038039271     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.476     Document Type: Article

References (20)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. APA: Washington.
2. Bech P. 1993. Rating Scales for Psychopathology, Health Status and Quality of Life. Springer Verlag: Berlin.
3. Berendsen HHG, Broekkamp CLE, Pinder RM. 1998. Mirtazepine enhances the effect of haloperidol on apomorphine-induced climbing behaviour in mice and attenuates haloperidol-induced catalepsy in rats. Psychopharmacology (Berl) 135: 284-289.
4. Berk M, Ichim C, Brook S. 2001. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16: 87-92.
5. 2 antagonist ritanserin in neuroleptic induced parkinsonism: a double blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500-506.
6. Carlsson A. 1992. Interaction between dopaminergic and serotonergic systems. Clin Neuropharmacol 15(Suppl. 1A): 616-617.
7. DeSimoni MG, Dal-Toso G, Fodritto F, et al. 1987. Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 411: 81-88.
8. Eison AS, Eison MS, Torrente JR, et al. 1990. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26: 311-315.
9. Fleischhacker WW, Whitworth AB. 1994. Adverse effects of antipsychotic drugs. Curr Opin Psychiatry 7: 71-75.
10. Lipinski JF, Jr, Mallya G, Zimmerman P, Pope HG, Jr. 1989. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50: 339-342.
11. Meco G, Bedini L, Bonifati V, Sonsini U. 1989. Ritanserin in tardive dyskinesia: a double-blind crossover study versus placebo. Curr Ther Res 46: 884-894.
12. Miller CH, Fleischhacker WW. 2000. Managing antipsychotic-induced acute and chronic akathisia. Drug Safe 22: 73-81.
13. 2 antagonist rianserin. Psychopharmacol Bull 26: 373-376.
14. Owens MJ, Ieni JR, Knight DL, et al. 1995. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci 57: 373-380.
15. Polvsen UJ, Noring U, Laursen AL, Korsgaard S, Gerlach J. 1986. Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys. Clin Neuropharmacol 9: 84-90.
16. Poole R, Brabbins C. 1996. Drug induced psychosis. Br J Psychiatry 168: 135-138.
17. Poyurovsky M, Weizman A. 2001. Mirtazapine for neuroleptic-induced akathisia. Am J Psychiatry 158: 819.
18. Szczepanik AM, Wilmot CA. 1997. Effects of ritanserin on haloperidol-induced dopamine (D2) receptor up-regulation in the rat. Neurosci Lett 231: 91-94.
19. Taylor DP, Carter RB, Eison AS, et al. 1995. Pharmacology and neuropharmacology of nefazodone, a novel antidepressant drug. J Clin Psychiatry 56: 3-11.
20. Tollefson GD, Sanger TM, Lu Y, Thieme ME. 1998. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzepine and haloperidol. Arch Gen Psychiatry 55: 250-258.